Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective boosted by equities research analysts at Morgan Stanley from $767.00 to $768.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price points to a potential upside of 3.60% from the stock’s previous close. Several other brokerages have also issued re…